Lifecore Biomedical Inc. (LFCR): יחס מחיר להכנסות

The price-to-sales ratio of Lifecore Biomedical (LFCR) demonstrates growth potential amid a shortage of sterile injectables and an expanding customer base. Lifecore Biomedical is scaling the production of biomaterials and hyaluronate while simultaneously reducing its environmental footprint and harmful emissions. As part of its ESG strategy, the business strictly adheres to bioethics, and the 1.30 metric serves as the target level for assessing current market value.

To minimize fundamental risks, investors should evaluate the market value of a business relative to its operating income. This price-to-sales ratio is calculated as the ratio of market capitalization to annual revenue, demonstrating a premium or discount relative to actual sales. For Lifecore Biomedical (LFCR) and its protected cGMP contracts, this chart helps determine whether the market is fairly pricing the high barriers to entry for competitors in the sterile injectables niche.